Invention Grant
US09075066B2 CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer
有权
CST1，DCC1，IFITM1或MELK作为诊断胃癌的标记物
- Patent Title: CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer
- Patent Title (中): CST1，DCC1，IFITM1或MELK作为诊断胃癌的标记物
-
Application No.: US12679879Application Date: 2009-04-21
-
Publication No.: US09075066B2Publication Date: 2015-07-07
- Inventor: Hee Gu Lee , Eun Young Song , Min Ah Kang , Jong Tae Kim , Jae Wha Kim , Young Il Yeom , Seon Young Kim , Kyung Chan Park
- Applicant: Hee Gu Lee , Eun Young Song , Min Ah Kang , Jong Tae Kim , Jae Wha Kim , Young Il Yeom , Seon Young Kim , Kyung Chan Park
- Applicant Address: KR Daejeon
- Assignee: Korea Research Institute of Bioscience and Biotechnology
- Current Assignee: Korea Research Institute of Bioscience and Biotechnology
- Current Assignee Address: KR Daejeon
- Agency: Seed IP law Group PLLC
- Priority: KR10-2008-0036867 20080421; KR10-2008-0036868 20080421; KR10-2008-0036869 20080421; KR10-2008-0036870 20080421
- International Application: PCT/KR2009/002084 WO 20090421
- International Announcement: WO2009/131365 WO 20091029
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/574 ; C12Q1/68
Abstract:
The present invention relates to a biomarker for gastric cancer, CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (Defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase). More particularly, the present invention relates to a diagnostic composition for gastric cancer comprising an agent measuring the expression level of CST1, DCC1, IFITM1 or MELK, a kit comprising the composition, a method for detecting the marker, and a method for screening a therapeutic agent for gastric cancer using the marker.
Public/Granted literature
- US20110152106A1 CST1, DCC1, IFITM1 OR MELK AS MARKERS FOR DIAGNOSING STOMACH CANCER Public/Granted day:2011-06-23
Information query
IPC分类:
